Top Story
Mounting Attack on Drug Pricing: Will ICER Be the De Facto NICE in the US?
With biopharma companies increasingly accused of bankrupting the health care system with high prices, news that ICER has received a $5.2 million grant to expand its analyses of drug cost-effectiveness could be a game changer, writes Jill Wechsler
...Read more

What are the biggest challenges to oncologists using immunotherapies? Read the report to find out.

Compliance
Stop Everything! Investigating FCPA Issues in Pharma
An internal audit of payment practices in Eastern Europe has revealed payments for elaborate travel for government health authorities and state-employed physicians in exchange for approval and prescription of your products. What is the first thing you should do? Lawyer Mara Senn offers some advice
...Read more

No Access, No Business: The rocky road to Market Access Excellence
Live Webinar: Tuesday, 1 September 2015 at 11 am EDT / 4 pm BST / 5 pm CEST No access = no business!
Market Access needs to be the most important function in your organization. Transforming this function to fulfill that key role is difficult, but possible. Learn in our webcast how to achieve true Excellence in Market Access and be ready for future challenges.
Register for free

Regulatory
Biosimilars: The Next Chapter
Casey McDonald speaks with legal experts about last week’s Amgen/Sandoz decision from the U.S. Court of Appeals for the Federal Circuit in Washington
...Read more

On the road to integration
Moving your multichannel program into the fast lane
On Demand
Join Peter Lammers and Liz Murray from Quintiles as they present insightful research findings regarding the state of the pharmaceutical industry and the use of multi-channel marketing strategies. Learn what other industries apply successfully and get different options for you to actually “make it happen” for your product.
Register for free

Emerging Pharma Leaders
Pharm Exec’s Emerging Pharma Leaders 2015
The 2015 Emerging Pharma Leaders have been selected by PharmExec’s editorial staff with support from its Editorial Advisory Board. This year’s group adds to a list of more than 200 alumni dating back to June 2008. We called that first cohort of leaders “the change generation” and frankly the description remains apt today. What is different is a greater diversity in leader backgrounds and the skills required to advance to the “c-suite”
...Read more

Emerging Pharma Leaders — Slide Show
If you’re pressed for time and want just the names and faces, click here for a slide show of PharmExec’s 17 Emerging Pharma Leaders 2015
...Read more

//Turing Pharmaceuticals (New York, NY) added former Johnson & Johnson communications executive and branding specialist Craig Rothenberg as the company’s first Chief Communication Officer. //Genomatica (San Diego, CA) announced the appointment of Carlos A. Cabrera to its Board of Directors as Executive Chairman. //Radius Health, Inc. (Waltham, MA) hired Dr. Lorraine A. Fitzpatrick as Chief Medical Officer. //Keryx Biopharmaceuticals (Boston, MA) appointed Scott A. Holmes as Chief Financial Officer. //CASI Pharmaceuticals (Rockville, MD) has appointed leading oncology experts Ghassan K. Abou-Alfa, M.D., Gail Eckhardt, M.D., Robert J. Mayer, M.D., and Rong Chen, M.D., Ph.D., to its newly formed Clinical Advisory Board. //